Imidaprilat is the active diacid metabolite of imidapril, an angiotensin-converting enzyme (ACE) inhibitor. It inhibits ACE, an enzyme involved in the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone-mediated sodium retention.
Imidaprilat is primarily relevant as the pharmacologically active metabolite of imidapril and is used in pharmaceutical and pharmacological research related to ACE inhibition, hypertension and cardiovascular regulation.
Imidaprilat is a specialized pharmaceutical compound requiring controlled synthesis, purification and analytical characterization. As a polar diacid metabolite, its physicochemical properties differ from those of the lipophilic prodrug imidapril.
Quality evaluation may include identity, assay, related substances, water content, residual solvents, elemental impurities and stereochemical purity, where applicable.
CAS Number: 89371-44-8
Molecular Formula: C20H27N3O6
Molecular Weight: 405.45 g/mol
Chemical Name: Imidaprilat
Drug Class: ACE Inhibitor
Pharmacological Class: Angiotensin-Converting Enzyme Inhibitor
Therapeutic Class: Antihypertensive / Cardiovascular Agent
Therapeutic Area: Cardiovascular
Imidaprilat inhibits angiotensin-converting enzyme (ACE).
ACE catalyzes the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. Inhibition of ACE reduces angiotensin II formation and consequently decreases vasoconstriction and aldosterone secretion.
ACE inhibition also reduces the breakdown of bradykinin, contributing to the pharmacological effects associated with ACE inhibitors.
Imidapril is administered as a prodrug and is metabolized in the body to its active diacid metabolite, Imidaprilat.
Therefore, Imidaprilat is important in understanding the pharmacological activity of imidapril-based therapy and is also used as a reference compound in pharmacokinetic and analytical studies.
Imidaprilat is relevant to pharmaceutical research involving:
The marketed pharmaceutical use of imidapril is distinct from the use of isolated Imidaprilat as an active pharmaceutical ingredient.
By inhibiting ACE, Imidaprilat reduces the formation of angiotensin II and alters the renin-angiotensin-aldosterone system. This mechanism is central to the antihypertensive action of ACE-inhibiting drugs.
Imidaprilat is a synthetic, nitrogen-containing organic compound with multiple oxygen-containing functional groups. Its structure contains carboxylic acid functionality associated with its active diacid metabolite.
Its physicochemical characteristics, including aqueous solubility and solid-state properties, should be considered during analytical method development and formulation research.
Imidaprilat quality evaluation may include:
Imidaprilat should be stored in a tightly closed container under controlled pharmaceutical conditions and protected from excessive moisture, heat and direct light. Final storage conditions should be established using validated stability data.
Imidaprilat is relevant to research involving ACE inhibitors, angiotensin II regulation, cardiovascular pharmacology, hypertension, drug metabolism and pharmacokinetic analysis.
Imidaprilat is the active diacid metabolite of imidapril and an ACE inhibitor with CAS Number 89371-44-8, molecular formula C20H27N3O6, and molecular weight 405.45 g/mol. It inhibits ACE and is particularly relevant to research involving the renin-angiotensin system and imidapril pharmacology.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 2.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 2.0% |
| Water Content | NMT 2.0% |